Application No. 10/550,778 Preliminary Amendment dated May 5, 2008 Docket No. 753-54 PCT/US Page 3

REMARKS/ARGUMENTS

In the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on March 3, 2008, the Office indicated that an amendment directing entry of the sequence listing into the application is required to place the application into conformance with the requirements of 37 CFR 1.821-1.825. In response, the specification has been amended herein to direct entry of the paper and computerreadable copies of the sequence listing being submitted concurrently herewith into the application.

Moreover, the specification has been amended at Table 1 with regard to SEQ ID NO:1 at P1' to replace "Lys" with --Arg--, thereby correcting an obvious error. It is respectfully submitted that support for the amendment to Table 1 may be found in the instant specification at claim 18 and, as such, it is respectfully submitted the amendment introduces no new matter. The paper and computer-readable copies of the sequence listing submitted herewith include this amendment to SEQ ID NO:1.

Should the Examiner have any questions concerning this response, the Examiner is respectfully invited to contact the undersigned at the telephone number set forth below.

The Commissioner is hereby authorized to charge payment of any fees associated with this communication, or credit any overpayment, to Deposit Account No. 08-2461. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 C.F.R. §1.17 and also should be treated as a constructive petition for an extension of time in this reply or any future reply pursuant to 37 C.F.R. §1.136.

Respectfully submitted,

Andrea M. Wilkovich Registration No.: 53,773

HOFFMANN & BARON, LLP 6900 Jericho Turnpike Syosset, New York 11791 (973) 331-1700

TEMPLATE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER Application No. 10/550,778 Inventors: Zumbrunn et al. Docket No 753-54 PCT/US

ANNOTATED SHEET

83

Table 1: Examples 1-6, n = 4, n=6

P6 P5 P4	P5' P4'	P4`		Д,	P3,	P2'	PI,	Template	P1	P2	P3	P4	_	Purity%³)[M+)[M+H]/2
Arg Arg 2-Nal Cys	Arg 2-Nal Cys	2-Nal Cys	Cys		•	Гу	LysArg	LystPro	Ty	či	Cys	Arg-NH2		86	862.6
Arg Arg 2-Nal Cys	Arg 2-Nal Cys	2-Nal Cys	Cys			Τ'n	Lys	DLys Pro	Ţ	Ċi	Cys	Arg-NH2		96	876.3
SEQ ID NO 3 Arg Arg 2-Na1 Cys 7	Arg 2-Nal Cys	2-Nal Cys	Cys		•	ľy	Lys	^D Lys ^L Pro	Arg	Ċį	Cys	Arg-NH ₂	3.28	6	858.4
Arg Arg 2-Nal Cys	Arg 2-Nal Cys	2-Nal Cys	Cys		•	ľ	Lys	Pro Pro	ТХ	Arg	Cys	Arg-NH2	•	001	845.9
Arg Arg 2-Nal Cys	Arg 2-Nal Cys	2-Nal Cys	Cys		•	Ty	Arg	Pro Pro	Tyt	Arg	Cys	Arg-NH2	•	86	0.098
Arg Arg 2-Nal Cys	Arg 2-Nal Cys	2-Nal Cys	Cys			Ľ	Arg	L Lys L Pro	Тут	či	Cys	Arg-NH2	4	96	875.9

a) %-puritity of compounds after prep. HPLC. cysteines at position P3 and P3 are linked by a disulfide bridge